Kangmei Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	1,181	977.84	1,057	1,507	2,419	552.34
Trading Asset Securities	0.09	0.08	0.08	0.12	0.52	-
Cash & Short-Term Investments	1,181	977.92	1,057	1,508	2,419	552.34
Cash Growth	52.63%	-7.45%	-29.90%	-37.68%	337.98%	8.93%
Accounts Receivable	2,574	2,542	2,249	2,046	1,460	2,487
Other Receivables	574.34	823.86	874.44	888.79	1,052	9,559
Receivables	3,149	3,366	3,123	2,935	2,512	12,046
Inventory	2,453	2,510	2,644	2,751	3,195	5,709
Prepaid Expenses	-	-	-	0	-	0.01
Other Current Assets	247.29	45.65	-14.11	190.85	158.8	234.39
Total Current Assets	7,029	6,900	6,810	7,384	8,285	18,541
Property, Plant & Equipment	3,333	3,500	3,875	4,180	4,642	9,603
Long-Term Investments	1.05	1.11	1.15	1.39	1	1
Goodwill	106.35	106.35	106.35	106.35	106.35	36.91
Other Intangible Assets	391.48	409.47	491.02	529.79	579.73	1,309
Long-Term Deferred Tax Assets	67.53	74.36	101.48	96.97	60.69	240.96
Long-Term Deferred Charges	49.44	55.05	66.47	86.71	110.22	111.57
Other Long-Term Assets	2,705	2,752	2,829	2,783	2,269	3,483
Total Assets	13,683	13,798	14,280	15,169	16,054	33,326
Accounts Payable	2,609	2,546	2,256	2,563	2,015	3,762
Accrued Expenses	58.81	520.42	716.97	1,328	1,134	2,066
Short-Term Debt	14.84	15.83	26.14	25.62	15.17	2,315
Current Portion of Leases	25.3	28.35	40.71	39.12	36.89	-
Current Income Taxes Payable	418.71	27.7	24.74	26.2	140.5	112.15
Current Unearned Revenue	146.87	118.82	159.89	158.12	193.85	455.19
Other Current Liabilities	2,538	2,637	2,875	1,301	1,411	14,576
Total Current Liabilities	5,811	5,894	6,100	5,442	4,947	23,286
Long-Term Debt	-	-	-	-	-	19,415
Long-Term Leases	78.45	94.95	188.16	199.13	153.22	-
Long-Term Unearned Revenue	530.15	555.78	618.68	653.98	692.97	1,035
Long-Term Deferred Tax Liabilities	21.15	26.85	51.68	55.53	-	0.05
Other Long-Term Liabilities	17.09	17.79	241.31	1,835	293.02	-
Total Liabilities	6,458	6,589	7,200	8,185	6,086	43,736
Common Stock	13,829	13,864	13,864	13,864	13,864	4,974
Additional Paid-In Capital	18,474	18,783	18,783	18,783	18,783	11,576
Retained Earnings	-24,354	-24,367	-24,375	-24,478	-21,790	-29,706
Treasury Stock	-763.92	-1,107	-1,225	-1,222	-932.82	-343.6
Comprehensive Income & Other	1.23	1.18	1.18	1.43	3.1	-3.74
Total Common Equity	7,187	7,174	7,048	6,948	9,927	-13,504
Minority Interest	37.91	34.55	32.89	35.43	41.92	126.47
Shareholders' Equity	7,225	7,209	7,080	6,984	9,968	-10,410
Total Liabilities & Equity	13,683	13,798	14,280	15,169	16,054	33,326
Total Debt	118.59	139.13	255.01	263.87	205.29	21,730
Net Cash (Debt)	1,062	838.8	801.68	1,244	2,214	-21,178
Net Cash Growth	90.46%	4.63%	-35.54%	-43.82%	-	-
Net Cash Per Share	0.08	0.06	0.08	0.09	0.16	-1.53
Filing Date Shares Outstanding	13,829	13,864	13,864	13,864	13,864	4,974
Total Common Shares Outstanding	13,829	13,864	13,864	13,864	13,864	4,974
Working Capital	1,218	1,007	709.67	1,942	3,338	-4,745
Book Value Per Share	0.52	0.52	0.51	0.50	0.72	-2.71
Tangible Book Value	6,689	6,658	6,450	6,312	9,240	-14,849
Tangible Book Value Per Share	0.48	0.48	0.47	0.46	0.67	-2.99
Buildings	-	5,119	5,229	5,401	5,665	8,359
Machinery	-	1,162	1,162	826.65	1,206	2,799
Construction In Progress	-	175.32	210.56	215.5	263.65	1,630

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.